SAN JOSE, Calif., Dec. 5, 2016 /PRNewswire/ -- Rani Therapeutics, an InCube Labs company, today announced that Boston Scientific executive, Maulik Nanavaty, is joining its Board. Nanavaty is currently Senior Vice President and President of Boston Scientific's Neuromodulation Division and a member of its Executive Committee. Prior to his eleven year tenure at Boston Scientific, Nanavaty held various executive positions at Baxter International, Inc. and Baxter Japan. Nanavaty is the second outside Board member to be named, following the recent addition of pharmaceutical industry veteran and former Allergan CEO, David Pyott.
Rani is developing a novel technology platform to convert injectable drugs such as TNF-alpha inhibitors, interleukin antibodies, basal insulin and GLP-1 into oral pills. Rani Therapeutics has signed on two pharmaceutical collaborations – Novartis and Astra Zeneca – in the last 18 months; raised more than $85 million; and has a solid IP portfolio with more than 30 issued patents, and 80+ patents filed.
"Rani is entering a critical growth stage, and it is a perfect time to bring Maulik onto our Board," said Mir Imran, Chairman & CEO of Rani Therapeutics. "Maulik has deep expertise in developing and commercializing innovations both in med tech and pharma, based on his many years with Boston Scientific and Baxter. His perspective will be invaluable as we move towards clinical validation and commercialization of our platform."
"With Rani's oral biologics platform, Mir and the Rani team have created something very special and potentially ground breaking in the pharma world," said Maulik Nanavaty. "I am excited to help the company realize its potential, and eventually bring this innovative technology to millions of patients who endure regular, painful injections."
Prior to Nanavaty's current role at Boston Scientific, Nanavaty was President and Representative Director of Boston Scientific Japan. Previously, he was Vice President and General Manager of the Company's Interventional Cardiology business in Japan where he managed the successful expansion of Cardiology business in that country. He joined Boston Scientific in 2005 as Vice President for Corporate Strategy for Japan, where he led business transformation and increased operational efficiency. Prior to joining Boston Scientific, Nanavaty spent 16 years working in various executive positions at Baxter International Inc. and Baxter Japan. Nanavaty earned his doctorate in pharmaceutical sciences from the University of Illinois and his master's degree in business administration from the University of Chicago.
About Rani Therapeutics Founded in 2012, Rani Therapeutics has developed a novel approach for the oral delivery of peptides, proteins and therapeutic antibodies which to date can only be delivered through injections. The approach and technology for Rani Therapeutics was developed at InCube Labs, a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations. InCube is led by Mir Imran, a prolific medical inventor, entrepreneur and investor, who has founded more than 20 life sciences companies and holds more than 400 patents issued and pending in the US. Many of Imran's innovations have resulted in new standards of care, including the first FDA-approved Automatic Implantable Cardioverter Defibrillator. For more information, please visit: www.ranitherapeutics.com and www.incubelabs.com.
Advertisement
Rani is developing a novel technology platform to convert injectable drugs such as TNF-alpha inhibitors, interleukin antibodies, basal insulin and GLP-1 into oral pills. Rani Therapeutics has signed on two pharmaceutical collaborations – Novartis and Astra Zeneca – in the last 18 months; raised more than $85 million; and has a solid IP portfolio with more than 30 issued patents, and 80+ patents filed.
Advertisement
"Rani is entering a critical growth stage, and it is a perfect time to bring Maulik onto our Board," said Mir Imran, Chairman & CEO of Rani Therapeutics. "Maulik has deep expertise in developing and commercializing innovations both in med tech and pharma, based on his many years with Boston Scientific and Baxter. His perspective will be invaluable as we move towards clinical validation and commercialization of our platform."
"With Rani's oral biologics platform, Mir and the Rani team have created something very special and potentially ground breaking in the pharma world," said Maulik Nanavaty. "I am excited to help the company realize its potential, and eventually bring this innovative technology to millions of patients who endure regular, painful injections."
Prior to Nanavaty's current role at Boston Scientific, Nanavaty was President and Representative Director of Boston Scientific Japan. Previously, he was Vice President and General Manager of the Company's Interventional Cardiology business in Japan where he managed the successful expansion of Cardiology business in that country. He joined Boston Scientific in 2005 as Vice President for Corporate Strategy for Japan, where he led business transformation and increased operational efficiency. Prior to joining Boston Scientific, Nanavaty spent 16 years working in various executive positions at Baxter International Inc. and Baxter Japan. Nanavaty earned his doctorate in pharmaceutical sciences from the University of Illinois and his master's degree in business administration from the University of Chicago.
About Rani Therapeutics Founded in 2012, Rani Therapeutics has developed a novel approach for the oral delivery of peptides, proteins and therapeutic antibodies which to date can only be delivered through injections. The approach and technology for Rani Therapeutics was developed at InCube Labs, a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations. InCube is led by Mir Imran, a prolific medical inventor, entrepreneur and investor, who has founded more than 20 life sciences companies and holds more than 400 patents issued and pending in the US. Many of Imran's innovations have resulted in new standards of care, including the first FDA-approved Automatic Implantable Cardioverter Defibrillator. For more information, please visit: www.ranitherapeutics.com and www.incubelabs.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/maulik-nanavaty-joins-rani-therapeutics-board-300372422.html
SOURCE Rani Therapeutics
